Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872.
A total of 62 patients with metastatic or locally advanced non-small-cell lung cancer were entered in a phase II study of ACNU. Initially, the drug was given i.v. at a dose of 100 mg/m2 every 6 weeks, but due to observed haematological side effects in chemotherapy-pretreated patients, the dose was lowered in this group to 75 mg/m2. We observed one complete response in a subject exhibiting multiple lung metastases and a partial response in two patients, one showing brain metastases and one who experienced local disease recurrence. The toxicity of ACNU mainly consisted of bone marrow suppression especially thrombocytopenia, with one toxic death occurring due to intracerebral haemorrhage. We concluded that at this dose and on this schedule, ACNU has limited activity in non-small-cell lung cancer.
Planting
A S
AS
Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Ardizzoni
A
A
Estapé
J
J
Giaccone
G
G
Scagliotti
G
G
Splinter
T A
TA
Kirkpatrick
A
A
Dalesio
O
O
McVie
J G
JG
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015376:Nimustine / Q000009:adverse effects / Q000627:therapeutic use*
D015376:Nimustine